|
KaloBios to Stop KB003 Development for Asthma
Zacks.com KaloBios Pharmaceuticals, Inc. (KBIO – Snapshot Report) announced disappointing top line results from a phase II study on KB003 in patients suffering from severe asthma, where the candidate failed to meet the key endpoints. We expect the news to have a … KaloBios calls it quits on its asthma drug after a Phase II flop KaloBios Pharma pulls plug on asthma drug, shares plunge KaloBios Shares Slide on Move to Stop Asthma Treatment Study |
View full post on asthma – Google News